Hypertension Clinical Trial
— MyHEARTOfficial title:
The MyHEART Study: A Young Adult Hypertension Self-Management Randomized Controlled Trial
Verified date | May 2023 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a 5-year randomized controlled trial in two large healthcare systems (Madison and Milwaukee, WI) to evaluate MyHEART's (My Hypertension Education And Reaching Target) impact on blood pressure among 310 geographically and racially/ethnically diverse young adults.
Status | Completed |
Enrollment | 316 |
Est. completion date | February 8, 2022 |
Est. primary completion date | January 13, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 39 Years |
Eligibility | Inclusion Criteria: - Willing and capable of giving written informed consent - Willing to comply with all study procedures and be available for the duration of the study - Males and females ages 18-39 years old at the start of the study (inclusive) - A minimum of two hypertension ICD-10 coded visits with a provider (physician [MD, DO], physician assistant, nurse practitioner) on different dates in the last 24 months, with at least one code in the past 18 months - Medically homed at an IRB approved healthcare system Exclusion Criteria: - History of medically determined Congestive Heart Failure - Unable to provide informed consent (i.e., activated healthcare power of attorney) - Unable or unwilling to travel to local clinic for research visits - Currently residing in a skilled nursing facility - Diagnosed with sickle cell anemia or cystic fibrosis - Diagnosed with stroke, myocardial infarction, and/or coronary artery revascularization in the past 2 years - Syncope while exercising or doing strenuous activity within past 12 months - Currently prescribed warfarin, novel oral anticoagulant, or insulin - Planned organ transplant or prior transplant in the past 5 years - Chemotherapy or radiation therapy within 6 the past months - Severely impaired hearing, vision, or speech, as determined by study staff responsible for enrollment - Current participation or planning to participate in another clinical trial in the next 12 months - Pregnant or planning to become pregnant in the next 12 months - Planning to leave the geographic area in the next 6 months - Health condition that will limit both increasing physical activity and changing diet - Illegal drug use (other than marijuana) in the past 30 days - Unable to read or communicate in English - Currently on dialysis or seeing a Nephrologist - Unaware or denies history of high blood pressure or hypertension - Between-arm blood pressure difference >20 mmHg - White Coat Hypertension (24-hour ambulatory monitoring) - Inability to comply with or complete the protocol or other reasons at the discretion of the principal and site investigators - Prisoners |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin School of Medicine & Public Health | Madison | Wisconsin |
United States | Aurora Health Care | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | Aurora Health Care, National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Johnson HM, Sullivan-Vedder L, Kim K, McBride PE, Smith MA, LaMantia JN, Fink JT, Knutson Sinaise MR, Zeller LM, Lauver DR. Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial. Contemp Clin Trials. 2019 Mar;78:88-100. doi: 10.1016/j.cct.2019.01.010. Epub 2019 Jan 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Health Coach Fidelity to the Study Intervention | Evaluation of health coach fidelity to administering the motivational interviewing intervention per protocol will be assessed every 2 months using a modified Behavior Change Counseling Index | through completion of administering the study intervention, an average of 4 years | |
Other | Adverse Events | Number and type of adverse events | Through study completion, an average of 5 years | |
Other | Serious Adverse Events | Number and type of serious adverse events | Through study completion, an average of 5 years | |
Other | Withdrawal | Subject Withdrawal Rate | Through study completion, an average of 5 years | |
Primary | 24-hour Systolic Ambulatory Blood Pressure (mmHg) | 24-hour Systolic Ambulatory Blood Pressure measured at baseline, 6 months, and 12 months. | baseline, 6 month, and 12 month follow-up | |
Primary | 24-hour Diastolic Ambulatory Blood Pressure (mmHg) | 24-hour Diastolic Ambulatory Blood Pressure measured at baseline, 6 months, and 12 months. | baseline, 6 month, and 12 month follow-up | |
Primary | Clinic Systolic Blood Pressure (mmHg) | Systolic Blood Pressure measured at baseline, 6 months, and 12 months. | baseline, 6 month, and 12 month follow-up | |
Primary | Clinic Diastolic Blood Pressure (mmHg) | Clinic Diastolic Blood Pressure measured at baseline, 6 months, and 12 months. | baseline, 6 month, and 12 month follow-up | |
Secondary | Number of Participants That Achieve Hypertension Control at 6 Months | Hypertension Control: Percentage of participants that achieve hypertension control at 6 months. Hypertension control will be defined using ambulatory blood pressures as the gold standard (<130/80 mmHg); otherwise a clinic blood pressure of <140/90 mmHg will be used. | up to 6 months | |
Secondary | Sodium Intake as Assessed by the Automated Self-Administered 24-hour Dietary Assessment | Mean daily sodium intake (milligrams/day) at baseline, 6 months, and 12 months as assessed by the computer administered Automated Self-Administered 24-hour Dietary Assessment | baseline, 6 month, and 12 month follow-up | |
Secondary | Number of Combined Fruit and Vegetable Servings as Assessed by the Automated Self-Administered 24-hour Dietary Assessment | Mean number of combined fruit and vegetable servings measured at baseline, 6 months, and 12 months as assessed by the computer administered Automated Self-Administered 24-hour Dietary Assessment, reported in cups equivalent. | baseline, 6 month, and 12 month follow-up | |
Secondary | Ounces of Whole Grain as Assessed by the Automated Self-Administered 24-hour Dietary Assessment | Ounces of whole grain measured at baseline, 6 months, and 12 months as assessed by the computer administered Automated Self-Administered 24-hour Dietary Assessment | baseline, 6 month, and 12 month follow-up | |
Secondary | Saturated Fat as Assessed by the Automated Self-Administered 24-hour Dietary Assessment | Saturated fat measured at baseline, 6 months, and 12 months as assessed by the computer administered Automated Self-Administered 24-hour Dietary Assessment, reported in percent kilocalories | baseline, 6 month, and 12 month follow-up | |
Secondary | Physical Activity as Assessed by the Godin Physical Activity Questionnaire | Mean weekly amounts of physical activity as assessed by the Godin Physical Activity Questionnaire. The Godin Physical Activity Questionnaire measures a person's strenuous, moderate, and light physical activity in a week. Scoring is calculated as follows (units are times per week that the participant engaged in any of the 3 classifications of activity longer than 15 minutes during their free time):
9 x strenous units reported + 5 x moderate units reported + 3 x light units reported = score A minimum score of 0 indicates no activity, a score of less than 14 is interpreted as insufficiently active or sedentary, a score between 14 and 23 is interpreted to be moderately active, and a score of 24 and higher is interpreted to be active, a theoretical maximum does not exist. |
baseline, 6 month, and 12 month follow-up | |
Secondary | Home Blood Pressure Monitoring Frequency | Self-report of home blood pressure monitoring frequency measured at baseline, 6 months, and 12 months. | baseline, 6 month, and 12 month follow-up | |
Secondary | Standing Weight (kg) | Weight (kg) measured at baseline, 6 months, and 12 months. | baseline, 6 month, and 12 month follow-up | |
Secondary | Perceived Competence as Assessed by the Perceived Competence Scale for Diet | Perceived competence measured at baseline, 6 months, and 12 months as assessed by the Perceived Competence Scale (self-administration). This is a 4-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score from 1-7 will be reported with higher scores indicating increased perceived competence. | baseline, 6 month, and 12 month follow-up | |
Secondary | Perceived Competence as Assessed by the Perceived Competence Scale for Exercise | Perceived competence measured at baseline, 6 months, and 12 months as assessed by the Perceived Competence Scale (self-administration). This is a 4-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score from 1-7 will be reported with higher scores indicating increased perceived competence. | baseline, 6 month, and 12 month follow-up | |
Secondary | Perceived Autonomy as Assessed by the Health Care Climate Questionnaire for Diet | Perceived autonomy measured at baseline, 6 months, and 12 months as assessed by the Health Care Climate Questionnaire (self-administration). This is a 6-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean between 1-7 will be reported with higher scores indicative of increased perceived autonomy. | baseline, 6 month, and 12 month follow-up | |
Secondary | Perceived Autonomy as Assessed by the Health Care Climate Questionnaire for Exercise | Perceived autonomy measured at baseline, 6 months, and 12 months as assessed by the Health Care Climate Questionnaire (self-administration). This is a 6-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean between 1-7 will be reported with higher scores indicative of increased perceived autonomy. | baseline, 6 month, and 12 month follow-up | |
Secondary | Autonomous Motivation as Assessed by the Treatment Self-Regulation Questionnaire for Diet | Autonomous motivation measured at baseline, 6 months, and 12 months as assessed by the Treatment Self-Regulation Questionnaire (self-administration). This is a 15-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score between 1 and 7 will be reported with higher scores indicative of increased autonomous motivation. | baseline, 6 month, and 12 month follow-up | |
Secondary | Autonomous Motivation as Assessed by the Treatment Self-Regulation Questionnaire for Exercise | Autonomous motivation measured at baseline, 6 months, and 12 months as assessed by the Treatment Self-Regulation Questionnaire (self-administration). This is a 15-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score between 1 and 7 will be reported with higher scores indicative of increased autonomous motivation. | baseline, 6 month, and 12 month follow-up | |
Secondary | Controlled Motivation as Assessed by the Treatment Self-Regulation Questionnaire for Diet | Controlled motivation measured at baseline, 6 months, and 12 months as assessed by the Treatment Self-Regulation Questionnaire (self-administration). This is a 15-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score between 1 and 7 will be reported with higher scores indicative of increased controlled motivation. | baseline, 6 month, and 12 month follow-up | |
Secondary | Controlled Motivation as Assessed by the Treatment Self-Regulation Questionnaire for Exercise | Controlled motivation measured at baseline, 6 months, and 12 months as assessed by the Treatment Self-Regulation Questionnaire (self-administration). This is a 15-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score between 1 and 7 will be reported with higher scores indicative of increased controlled motivation. | baseline, 6 month, and 12 month follow-up | |
Secondary | Amotivation as Assessed by the Treatment Self-Regulation Questionnaire for Diet | Amotivation measured at baseline, 6 months, and 12 months as assessed by the Treatment Self-Regulation Questionnaire (self-administration). This is a 15-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score between 1 and 7 will be reported with higher scores indicative of increased amotivation. | baseline, 6 month, and 12 month follow-up | |
Secondary | Amotivation as Assessed by the Treatment Self-Regulation Questionnaire for Exercise | Amotivation measured at baseline, 6 months, and 12 months as assessed by the Treatment Self-Regulation Questionnaire (self-administration). This is a 15-item survey scored on a 7 point likert scale from 1 (not at all true) to 7 (very true). Mean score between 1 and 7 will be reported with higher scores indicative of increased amotivation. | baseline, 6 month, and 12 month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |